News

MLL Magazine

Stay up to date. The MLL Munich Leukemia Laboratory stands for innovation and the best leukemia diagnostics. Here you will find the latest research and study results related to hematological diagnostics and the therapy based on them, as well as other exciting news and events.

The magazine
Newsletter
Newsletter archive
Contact

The magazine

Anja Neumayer
at 19.04.2022

The contact point for all departments – the MLL Secretariat – introduces itself

Every day, the MLL team works together to provide patients worldwide with the best possible therapy through rapid and targeted leukemia diagnostics. But what exactly does the day-to-day work of the more than 200 employees look like? What departments and areas are there? Our magazine series, “MLL introduces itself”, provides you with an insight into our laboratory, with the third section introducing you to our secretariat.

Dr. rer. nat. Manja Meggendorfer, MBA
at 19.04.2022

Our new website has arrived

Over the last two years we have worked hard on our brand architecture, developing it further, and making it fit for the future. During the course of this we have harmonized the layout of our websites and improved them by incorporating your feedback as a site user. The websites of MLL, MLL MVZ, and MLLSEQ are now available in a new and harmonized design. The goal was to increase the user-friendliness of the website and to allow for rapid and targeted navigation through its pages. We look forward to your visit and to your feedback!

at 21.03.2022

Integrated DNA Technologies Adds MLL Munich Leukemia Laboratory to Align Program

The MLL Munich Leukemia Laboratory has a new collaboration partner: Following the launch of the xGen™ NGS portfolio from global genomics solutions provider Integrated DNA Technologies, MLL has joined the Align program. As the first European partner in the program, MLL and IDT aim to jointly advance genomics research. Read all about the new collaboration in MLL Magazine.

Prof. Dr. med. Dr. phil. Torsten Haferlach
at 20.12.2021

We Want to Say Thank You: The MLL Annual Review for 2021

For us, too, 2021 was marked by the Corona pandemic. We look back on an exciting but also challenging year and thank all our employees, our senders and our partners. Thank you for your trust in us and our diagnostics.

Dr. rer. nat. Christine Käppel
at 18.12.2021

MLL Dx Successfully Accredited by the College of American Pathologists (CAP)

MLL Dx, the sister company of the Munich Leukemia Laboratory (MLL) with its MLLSEQ brand, was appraised by the College of American Pathologists (CAP) and successfully accredited according to their requirements. Since 2019, MLL Dx has been accredited according to the international standards DIN EN ISO 15189 “Medical Laboratories – Requirements for Quality and Competence” and DIN EN ISO/IEC 17025 “General Requirements for the Competence of Testing and Calibration Laboratories” by the Deutsche Akkreditierungsstelle (German Accreditation Body – DAkkS).

PD Dr. med. Gregor Hörmann, PhD
at 16.10.2021

Good Findings Start with Preanalytics – Our Sample Receipt Introduces Itself

Every day, the MLL team focuses its combined efforts on making it possible for patients around the world to receive the best therapy thanks to quick and targeted leukemia diagnostics. But how does a normal workday look for the 200 or so employees? What are the different departments and areas? Our new magazine series “Introducing MLL” will be offering you a glimpse into our laboratory. In the first part, we want to present our Sample Receipt area.

Dr. rer. nat. Sandra Weißmann
at 19.04.2022

Validation of the laboratory-specific conversion factor for BCR::ABL1 p210

The standardization of BCR::ABL1 quantification according to the international scale (IS) is of great importance for managing chronic myeloid leukemia (CML). The laboratory-specific conversion factor required for this is redetermined annually during quality assurance rounds. Over the last five years, MLL has been a member of the EUTOS project, in which, among other things, a procedure was developed to allow each and every laboratory to determine its own conversion factor in the future. We have collected the most important results of the project for you plus its associated future innovations.

Dr. rer. nat. Isolde Summerer
at 22.02.2022

CHIP highly relevant to individual risk profile for individuals aged ≥80 years

Clonal genetic changes in hematopoietic cells occur with increasing frequency with advancing age, even in individuals without hematological neoplasia. Due to the growing number of individuals aged ≥80 years in our society, the need arises to investigate the clinical relevance of such clonal hematopoiesis of indeterminate potential (CHIP). A recently published study by Rossi and colleagues (Blood 2021;138 (21): 2093–2105) examined blood samples from 1794 individuals aged ≥80 years who have not been diagnosed with hematological neoplasia for mutations in 47 genes implicated in myeloid neoplasia

Dr. rer. nat. Ines Schmidts
at 20.12.2021

63rd ASH Annual Meeting & Exposition – a Postscript

The 63rd Annual Meeting & Exposition of the American Society of Hematology was held on December 11-14 – this year as a hybrid event for the first time. The MLL team attended virtually with a total of 13 contributions. The main topics were the continuous improvement of today’s gold standard and the diagnostics of tomorrow, including the use of artificial intelligence (AI) in the clinical routine and research, along with genome-wide methods of WGS (whole genome sequencing) and WTS (whole transcriptome sequencing). We have summarized for you all of this year’s ASH presentations with MLL participation.

Dr. rer. nat. Manja Meggendorfer, MBA
at 20.12.2021

Hematological Whole Genome and Transcriptome Sequencing as a New Diagnostic Tool for Acute Leukemias

Various research projects have shown that new technologies such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) provide added value for patients with acute leukemia. In the coming year, the MLL will be offering both diagnostics using classical methods as well as WGS/WTS analysis for acute leukemia. We want to pass this added clinical value on to our patients while at the same time learning from the knowledge gained. We also want to put WGS/WTS to the test in order to validate their clinical benefit.

Prof. Dr. med. Dr. phil. Torsten Haferlach
at 14.10.2021

A Difficult Case: What the Diagnostics of Tomorrow Will Look Like

We have all learned: “Common things are common, except when the diagnosis is rare.” So far so good. Thanks to the large number of cases with increasingly networked data and by taking the current WHO classification as a basis, it is possible for even rare diagnoses to be assigned with greater precision today. This becomes more difficult, however, if the individual findings of the diagnostics chain and the blood values do not fit together in a conclusive way – or if any uncertainty simply remains even though the patient is definitely clinically ill. So what is the next step?

Dr. rer. nat. Anna Stengel
at 18.08.2021

CLL: The more complex the karyotype, the less favorable the prognosis

In addition to TP53 alterations and IGHV mutation status, a complex karyotype is also considered a genetic risk factor of chronic lymphocytic leukemia (CLL). However, the cytogenetics/chromosome analysis required to detect a complex karyotype has often not been an integral part of CLL diagnostics to date. New data now show that as the number of cytogenetically detected chromosomal alterations increases, survival of treated CLL patients decreases. These results are summarized here.

Dr. rer. nat. Constanze Kühn
at 16.08.2021

MTLAs, doctors and artificial intelligence at MLL – a good team!

We take artificial intelligence (AI) for granted these days and often use it in our everyday lives without noticing. But what does this mean for diagnostics – today and in the future? At MLL, artificial intelligence is used in various areas of diagnostics and is constantly being further developed. This not only saves time but will also facilitate the training of new staff in the future and expand opportunities for global collaboration. The aim is to provide patients with easier access to precise and rapid diagnoses and thus access to the best possible therapy.

Dr. med. Christian Pohlkamp
at 06.08.2021

MLL and Institute of AI for Health of the Helmholtz Center of Munich Announce Research Collaboration

The Munich Leukemia Laboratory and the newly founded Institute of AI for Health (AIH) of the Helmholtz Center of Munich have agreed on comprehensive collaboration for research and development. The primary goal is the implementation of machine learning and artificial intelligence in various areas of leukemia diagnostics.

Prof. Dr. med. Dr. phil. Torsten Haferlach
at 30.09.2020

BELUGA - A Prospective, Registered Study on the Use of Artificial Intelligence (AI) in Hematology

Even before the start of the COVID-19 pandemic, we saw how strongly digitalization is shaping our private and professional lives and will continue to do so in the future. This also applies to innovations for daily work in the paperless Munich Leukemia Laboratory (MLL), such as the complete digitalization of all medical findings in a constantly improving digital infrastructure. However, AI will mark a new era for medical diagnostic services as well.

Dr. rer. nat. Ines Schmidts
at 18.02.2020

The Use of Artificial Intelligence at MLL Munich Leukemia Laboratory

Whether a search engine or digital assistant is involved, artificial intelligence (AI) has long been a part of our day-to-day work. There are success stories in imaging-based diagnostics thanks to AI as well. Preliminary studies, for example, indicate that the classification of medical findings using AI is equivalent to traditional methods.

Niroshan Nadarajah
at 18.11.2019

MLLi:ir - A diagnostic interpretation report for NGS data

Making a patient disease diagnosis on the basis of Next-Generation Sequencing (NGS) data is a complex endeavor. To be able to make an exact diagnosis, medical professionals must be able to access all the available information pertaining to the specific genetic variants detected.

Dr. Wencke Walter
at 15.03.2022

Leukaemia diagnosis – Realising the potential of whole transcriptome sequencing

In AML and ALL the application of WHO classification and ELN guidelines requires a plethora of methods to determine the diagnostic and prognostic subgroup. Especially in ALL, many different subtypes have been described, which makes accurate diagnosis a challenge. However, in recent years, whole genome and whole transcriptome sequencing have emerged as comprehensive high-throughput techniques that allow for an accurate genetic characterization. This identification of patients’ genetic fingerprint is key to a precise diagnosis and the design of personalised cancer treatments.

Dr. Wencke Walter
at 28.12.2021

Research Report 2021

Even though the last two years have been dominated by the pandemic, we have kept science firmly in our mind. Providing the best possible care for our oncology patients remains our heartfelt mission. After another scientifically successful year, we would like to take the opportunity to summarize our findings of 2021. To further facilitate reading and to better convey our data, we have included various graphical representations and summaries and we hope you enjoy the content.

Dr. Wencke Walter
at 10.02.2020

Genomic & Transcriptomic Data Visualization

Visualization of genomic and transcriptomic data is essential to easily exploring those large datasets for interpretation and hypothesis generation and can further help to uncover hidden patterns and trends. With the ongoing development of sequencing and computer technologies, it has become feasible for scientists and clinicians to reliably collect large amounts of high-quality sequence information from DNA and RNA molecules. The analysis and interpretation of such datasets are now routine aspects of many research projects in biology and medicine, creating a need for new tools and methods to also visualize the data and the findings.

Dr. Wencke Walter
at 04.12.2019

Analysis of pharmacogenomic variants by WGS data for AML patients with altered response to treatment

With the decrease of sequencing costs, the number of freely available "omics" data sets also increases, opening a nearly unlimited quantity of molecular genetic information. For the last decades the classical way of elucidating multifaceted molecular networks of diseases has been to break down the system into smaller, more traceable parts.

Dr. Wencke Walter
at 02.12.2019

AML and MDS – the ever-expanding potential of genetics to define clinically relevant subclasses

For nearly half a century acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) have been separated according to the percentage of bone marrow blasts. However, the last ten years have shown that the incorporation of genetic information in the classification improves its accuracy in diagnosis and prognosis.

Dr. Wencke Walter
at 18.08.2019

Large-scale sequencing experience from the MLL 5K project

The project was started in 2017 with the aim to sequence the genome and transcriptome of 5,000 patients with haematological malignancies, in order to obtain a more in-depth knowledge of their molecular profiles to better understand the underlying complexity, to refine diagnosis, and also to take another step in the direction of personalized medicine.

Currently there are no upcoming events.

You want to stay up to date? Get the latest news articles and announcements from our magazine sent to you? Then subscribe to our newsletter. You will receive it once a quarter by e-mail.

Our newsletter is an offer of MLL Münchner Leukämielabor GmbH (Max-Lebsche-Platz 31, 81377 Munich (“MLL,” “we”)) and contains information about our products and services, research results, events and other news relevant to the company and to the discipline, especially regarding diagnostics and subsequent therapy for leukemia and lymphoma. For you to subscribe, we need the e-mail address that you want us to send the newsletter to. We may use optional information to personalize how the addressee is addressed.
To continuously improve the quality of our newsletter and its contents, we conduct a pseudonymized analysis of the opening rate of the newsletter and information on calling up specific articles.

By clicking the “subscribe” button, I consent to allow MLL to use the e-mail address and optional information provided by me for sending the newsletter and for addressing me personally.

You may also be interested in

Big data

We provide scientists, researchers and physicians with browser-based tools for interpreting sequencing data for hematology diagnostics.

Learn more

Research

Through a large number of our in-house scientific projects as well as national and international collaborations, we contribute to the progress of leukemia and lymphoma diagnostics and risk stratification of patients.

Learn more

Career

As a rapidly growing, innovative medical laboratory, we are always looking for bright minds to help us bring new and more effective therapies to patients around the world.

Learn more

Your contact person

»Transparent communication both internally and externally is important to us.«

Sarah Gallinger

Head of Corporate Communication
Press and media contact

T: +49 (0)89 99017-547
sarah.kurz@mll.com

News

The magazine

Newsletter

Newsletter archive

You may also be interested in

Your contact person